{"api_version":"v1","slug":"tare-vs-sbrt-hcc-talk","name":"TARE vs SBRT for HCC: decision-making talk","occurrence_count":1,"occurrences":[{"date":"2026-10-03","conference":null,"disease_site":"hepatobiliary","study":{"name":"TARE vs SBRT for HCC: decision-making talk","tldr":"Both TARE and SBRT can deliver ablative RT in HCC; phenotype should pick the modality, SBRT attractive with MVI, arterial constraints, or non-invasive preference.","details":["🔍 Framing question: which approach can best deliver adequate dose safely and selectively for a given pt/tumor",{"text":"🔍 SBRT vs TARE: constraints by criterion (summary slide)","table":{"columns":["Criterion","SBRT","TARE"],"rows":[["Ablative potential","Yes","Yes"],["Abutting luminal GI structures","Can limit ablative dose; adaptive RT may expand feasibility","Often advantageous"],["Affected by lung shunt","No","Yes"],["Arterial anatomy","Independent","Dependent (arterial delivery)"],["Radiation delivery","Defined target + prospectively planned dose distribution","Arterial delivery + microsphere-dependent dose distribution"]]}},{"text":"🔍 Practical factors that may favor external beam/SBRT when either approach is technically feasible","subdetails":["No lung-shunt limitation, no dependence on arterial anatomy","No arterial access: potential advantage on blood thinners (ASA/Plavix for CVD, AC for PVT)","No sedation/anesthesia: potential advantage in older/frail pts or multiple comorbidities (EtOH/MASLD)","May simplify sequencing with systemic therapy (no need to hold anti-VEGF)"]},{"text":"🔍 SBRT feasibility check: can adequate tumor dose be delivered while...","subdetails":["Preserving functional liver","Minimizing dose to abutting stomach/duodenum","Maintaining adequate target coverage"]},{"text":"🔍 TARE feasibility check: can adequate tumor dose be absorbed given...","subdetails":["Arterial anatomy and microsphere distribution","Lung shunt","Uninvolved liver exposure"]},"🔗 BEACON-HCC (Hepatology 2026) includes SBRT & TARE as 1st line options","🔗 For BEACON class 1C, the slide lists both as options: SBRT or TARE preferred if performable selectively",{"text":"🔍 BEACON-HCC allocation domains (\"Beyond BCLC\")","subdetails":["Tumor burden & distribution: unifocal vs multifocal, tumor size, % liver involvement","Vascular invasion/spread: Vp1-2 vs Vp3-4, nodes/distant spread","Adverse tumor biology: tumor >8 cm, AFP >1000 ng/mL, poorly differentiated/infiltrative","Liver function + pt preference: liver dysfunction, portal hypertension, PS, goals"]},"⚠️ No outcome data (LC, OS, toxicity rates) on the shared slides; no effect size reported in source tweets","⚠️ Only a subset of the deck was shared; images not readable by this backend, analysis rests on OCR text"],"figures":[{"url":"https://pbs.twimg.com/media/HTtkN6fWQAAGY_J.jpg","caption":null},{"url":"https://pbs.twimg.com/media/HTtkMlpWgAAHHs_.jpg","caption":null},{"url":"https://pbs.twimg.com/media/HTtkLdWXwAAEC-X.jpg","caption":"BEACON class 1C case: SBRT and TARE feasibility considerations."},{"url":"https://pbs.twimg.com/media/HTtkP8rXsAAdOXO.jpg","caption":null}],"nct":null,"doi":null,"tweet_ids":[86],"slug":"tare-vs-sbrt-hcc-talk","significance":"The decision is modality selection for ablative RT in HCC when both SBRT and TARE are feasible. The slides give no outcome comparison; the tie-breakers offered are operational: lung shunt, arterial anatomy, anticoagulation, anesthesia risk, and not having to hold anti-VEGF. Abutting stomach/duodenum is the stated scenario where SBRT dose can be limited and TARE is often advantageous.","monday_clinic":"In HCC where either ablative RT approach is technically feasible, this supports weighing MVI, arterial constraints, anticoagulation, frailty and anti-VEGF timing toward SBRT; it does not extend to tumors abutting luminal GI structures, where SBRT ablative dose can be limited.","primary_endpoint":null,"analysis_sections":[{"label":"Radiotherapy","body":"SBRT delivers a **defined target with a prospectively planned dose distribution**; TARE dose distribution is **arterial and microsphere-dependent**. No dose, fractionation or dosimetry thresholds appear on the shared slides."},{"label":"vs leading data","body":"The talk positions itself against BCLC (\"Beyond BCLC\") and leans on **BEACON-HCC** (Hepatology 2026), a North American consensus on treatment allocation that the slide says includes **SBRT & TARE as 1st line options**. No trial results are cited on the shared slides."},{"label":"Applies to","body":"Represents HCC where both SBRT and TARE are candidate ablative approaches, including the BEACON class 1C example. Does not represent settings where one modality is already excluded by liver function, lung shunt or arterial anatomy."},{"label":"Limitations","body":"Only some slides were shared, and they contain **no outcome or toxicity numbers**. The BEACON class 1C grid is partly illegible in OCR, so per-modality recommendation strengths cannot be reproduced."},{"label":"Discussion","body":"The argument reframes TARE vs SBRT as a **feasibility and selectivity question** per pt, then adds practical tie-breakers that mostly favor SBRT. It does not settle which modality gives better control or survival when both are feasible."}],"interpretation":null,"relevant_specialties":["radonc","medonc"],"significance_by_specialty":{"radonc":"The decision is SBRT vs TARE for ablative intent in HCC. The slides frame SBRT feasibility around functional liver sparing, dose to abutting stomach/duodenum and target coverage, with adaptive RT named as a way to expand feasibility. No dose or fractionation is given, and no outcome comparison.","medonc":"The systemic-therapy angle is sequencing: the slides state SBRT may simplify integration because anti-VEGF does not need to be held, and that no arterial access may help pts on anticoagulation for PVT. No data on combined SBRT plus systemic therapy outcomes are shown."},"open_questions":["Head-to-head SBRT vs TARE outcomes in HCC when both are feasible","Does adaptive RT expand SBRT feasibility for HCC abutting luminal GI structures?","SBRT timing with anti-VEGF systemic therapy in HCC"],"consort":null,"modality":"radiation","intent":null,"methodology":null,"content_type":"presentation","discussed_trials":["BEACON-HCC"],"presentation":{"speaker":"Dr. Nina Niu Sanford","summary":"The speaker argued that TARE and SBRT are both ablative RT options in HCC and that the choice should follow tumor and pt phenotype, not a default modality. The proposed framework asks which approach can deliver adequate dose safely and selectively: for SBRT, liver sparing, luminal GI abutment and target coverage; for TARE, arterial anatomy, lung shunt and uninvolved liver exposure. Practical factors (anticoagulation, frailty, no anesthesia, anti-VEGF sequencing) are presented as tilting toward SBRT when either is feasible. The framework rests on the BEACON-HCC consensus allocation and on feasibility reasoning.","critique":["The shared slides carry no comparative outcome data, so the framework rests on feasibility and convenience reasoning, not on head-to-head efficacy or toxicity evidence for SBRT vs TARE.","The practical-factors slide lists only what favors SBRT; the mirror case for TARE (luminal GI abutment, dose absorbed by tumor) gets far less development in the slides shared.","Anchoring the recommendation to a consensus allocation document means the listing of SBRT and TARE as options reflects panel opinion, not a measured outcome.","\"Phenotype should determine modality\" assumes the modalities are equivalently ablative once feasible; liver function limits and tumor size limits for each are not on the shared slides."]},"significance_perspective":"Radiation oncology","related_trials":[{"nct":"NCT07530172","brief_title":"Radioembolization Versus External Radiation Therapy","overall_status":"RECRUITING","phase":["PHASE2"],"enrollment_count":146,"primary_completion_date":"2028-12","brief_summary":"The proposed study is a single site, prospective, randomized phase 2 study to evaluate the efficacy and tolerability transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma. The SBRT arm of the trial will involve standard SBRT delivered over 3-5 fractions as tolerated with dose/total therapy adjusted as needed for safety. The TARE arm of the trial will involve a planning arteriogram followed by selective transarterial delivery of…","conditions":["Heptocellular Cancer"],"interventions":[{"name":"Transarterial Radioembolization","type":"RADIATION"},{"name":"Stereotactic Body Radiation Therapy (SBRT)","type":"RADIATION"}],"eligibility_brief":"Inclusion Criteria:\n\n* Ability to provide written informed consent and HIPAA authorization\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged ≥ 18 years at time of informed consent\n* No more than 3 lesions of HCC evaluated…","answers_question":"Head-to-head SBRT vs TARE outcomes in HCC when both are feasible","relevance_phrase":"randomized phase 2 TARE vs 3-5 fx SBRT, ≤3 HCC lesions"},{"nct":"NCT07293468","brief_title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"enrollment_count":106,"primary_completion_date":"2034-03","brief_summary":"The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic therapy in patients with large, locally advanced, unresectable Hepatocellular carcinoma (HCC).\n\nThe main question it aims to answer is whether Sequential TACE-SBRT potentially gives longer Progression-free survival (PFS) benefit with similar toxicities as compared with…","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":[{"name":"Transarterial chemoembolization (TACE)","type":"PROCEDURE"},{"name":"Stereotactic Body Radiation Therapy (SBRT)","type":"RADIATION"},{"name":"SIRT Yttrium-90","type":"RADIATION"},{"name":"Atezolizumab & Bevacizumab","type":"DRUG"}],"eligibility_brief":"Inclusion Criteria:\n\n* Patients diagnosed with HCC either by histology or by the American Association for the Study of Liver Diseases Criteria (AASLD) 2018\n* Patients age 18-80 years of age with HCCs deemed unresectable at the Multidisciplinary Team Meetings (MDTs) because of the following:\n* R0…","answers_question":"Head-to-head SBRT vs TARE outcomes in HCC when both are feasible","relevance_phrase":"TACE-SBRT vs Y90 SIRT then atezo/bev, PFS, large HCC"},{"nct":"NCT06768242","brief_title":"Part of the Modern Art Study","overall_status":"NOT_YET_RECRUITING","phase":["NA"],"enrollment_count":10,"primary_completion_date":"2025-12","brief_summary":"One of the possible treatments for patients with liver tumours (hepatocellular carcinoma (HCC) or liver metastases) at the Erasmus MC is stereotactic body radiation therapy (SBRT) on the Cyberknife. To spare the organs at risk, suboptimal coverage of the planning target volume is sometimes accepted. The Ethos treatment system is equipped with a novel cone-beam CT (CBCT), which provides higher quality images. This makes it possible to consider online adaptive radiotherapy with daily plan…","conditions":["HCC - Hepatocellular Carcinoma","Liver Metastases"],"interventions":[{"name":"Cone beam CT","type":"RADIATION"}],"eligibility_brief":"Inclusion Criteria:\n\n* Written informed consent;\n* Patient discussed in multidisciplinary tumor board;\n* Patient diagnosed with liver metastases and referred to the dept. of Radiotherapy for SBRT OR patient ≥65 years, diagnosed with HCC and referred to the dept. of Radiotherapy for SBRT;\n* Able to…","answers_question":"Does adaptive RT expand SBRT feasibility for HCC abutting luminal GI structures?","relevance_phrase":"online CBCT-adaptive liver SBRT where OARs limit coverage"},{"nct":"NCT05488522","brief_title":"SBRT With Atezo/Bev for HCC","overall_status":"RECRUITING","phase":["PHASE1"],"enrollment_count":18,"primary_completion_date":"2026-12","brief_summary":"A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)","conditions":["Hepatocellular Carcinoma"],"interventions":[{"name":"SBRT + atezolizumab and bevacizumab","type":"BIOLOGICAL"}],"eligibility_brief":"Inclusion Criteria:\n\n* Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated.\n\nExclusion…","answers_question":"SBRT timing with anti-VEGF systemic therapy in HCC","relevance_phrase":"phase 1 SBRT concurrent with atezo/bev, dose escalation"}],"related_trials_provenance":{"queries_fired":["hepatocellular carcinoma SBRT radioembolization","hepatocellular carcinoma adaptive radiotherapy","hepatocellular carcinoma SBRT bevacizumab"],"queries_failed":[],"candidates_returned":18,"fetched_at":"2026-10-05T04:17:33.404Z","rerank_outcome":"picked_N"},"source_ids":[{"type":"tweet","id":86}]}}]}